NIKKEI 225
39,651.63 +478.48 (+1.22%) HANG SENG
18,069.75 -3.15 (-0.02%) CRUDE OIL
81.25 +0.42 (+0.52%) GOLD FUTURES
2,328.20 -2.60 (-0.11%) DOW
39,112.16 -299.05 (-0.76%) Bitcoin GBP
48,652.14 +301.23 (+0.62%)
RespireRx Pharmaceuticals Inc. (RSPI)
| Previous close | 0.0029 |
| Open | 0.0028 |
| Bid | 0.0026 x 0 |
| Ask | 0.0027 x 0 |
| Day's range | 0.0026 - 0.0031 |
| 52-week range | 0.0006 - 0.0069 |
| Volume | |
| Avg. volume | 22,965,387 |
| Market cap | 1.227M |
| Beta (5Y monthly) | 1.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireRespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
Glen Rock, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Markets: RSPI) (RespireRx or the Company), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is delighted to announce that the Department of Defense (DOD) has approved a $1.8 million translational research award to Shirley Ryan AbilityLab to fund a two stage Phase 2A and 2B clinical study in order to determine
- GlobeNewswire
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that, as part of an ongoing collaboration, a scientist team led by Dr. David Fuller of the University of Florida has published a peer-reviewed research article describing the ability of CX173
- GlobeNewswire
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
Glen Rock, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that KRM-II-81, its lead GABAA receptor potentiator (GABAkine), has advanced to the next level of evaluation within the NIH HEAL Initiative® Preclinical Screening Platform for Pain (PSPP) pro
